391: Breaching the IBD efficacy ceiling, and sham surgeries

About this episode

The episode discusses the challenges in improving drug efficacy for inflammatory bowel disease and the FDA's approach to rare disease treatments with insights from Cameron Turtle of Spyre Therapeutics.

Will drugmakers finally be able to breach the efficacy ceiling in inflammatory bowel disease? And is the Food and Drug Administration being flexible enough with rare disease treatments? Spyre Therapeutics CEO Cameron Turtle joins the podcast to discuss his company's experimental IBD medications, and whether the drug industry is scraping the barrel in the search for better treatments. We also discuss the latest news in the life sciences, including the ongoing debate between the FDA and UniQure over its Huntington's disease therapy, as well as Moderna's mammoth patent settlement.

People in this episode

Guest: Cameron Turtle

Topics covered

• inflammatory bowel disease
• drug efficacy
• FDA regulations
• rare disease treatments
• life sciences news

Keywords

• IBD
• drugmakers
• FDA
• rare diseases
• Huntington's disease
• Moderna
• patent settlement

Mentioned in this episode

Organizations: Food and Drug Administration, Spyre Therapeutics, UniQure, Moderna

More episodes of The Readout Loud

• 405: An obesity drug deep-dive, and peptides move mainstream · June 11, 2026 · 36 min
• 404: What RevMed's pancreatic cancer drug meant for one patient · June 4, 2026 · 38 min
• 403: Biotech exec Jeremy Levin on the industry's strategic turning point · May 28, 2026 · 47 min
• 402: Guarding biotech from China and big bets in longevity · May 21, 2026 · 44 min
• 401: Makary’s departure and Cassidy’s tenuous Senate seat · May 14, 2026 · 41 min
• 400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles · May 7, 2026 · 33 min